Trifecta Capital Advisors LLC Purchases 131 Shares of Eli Lilly and Company (NYSE:LLY)

Trifecta Capital Advisors LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 21,947 shares of the company’s stock after acquiring an additional 131 shares during the period. Eli Lilly and Company accounts for approximately 4.1% of Trifecta Capital Advisors LLC’s investment portfolio, making the stock its 8th biggest holding. Trifecta Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $19,444,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in LLY. LifeSteps Financial Inc. grew its stake in Eli Lilly and Company by 20.1% during the third quarter. LifeSteps Financial Inc. now owns 359 shares of the company’s stock worth $318,000 after purchasing an additional 60 shares during the period. Global Retirement Partners LLC boosted its holdings in shares of Eli Lilly and Company by 2.0% during the 3rd quarter. Global Retirement Partners LLC now owns 18,983 shares of the company’s stock worth $16,818,000 after buying an additional 380 shares in the last quarter. Good Life Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 14.4% during the 3rd quarter. Good Life Advisors LLC now owns 2,973 shares of the company’s stock worth $2,635,000 after buying an additional 374 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter worth approximately $354,000. Finally, Summit Financial Strategies Inc. increased its stake in shares of Eli Lilly and Company by 0.5% in the 3rd quarter. Summit Financial Strategies Inc. now owns 2,105 shares of the company’s stock valued at $1,865,000 after acquiring an additional 11 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $917.18 on Friday. Eli Lilly and Company has a 52 week low of $547.61 and a 52 week high of $972.53. The company’s 50 day moving average price is $920.70 and its two-hundred day moving average price is $856.27. The stock has a market cap of $871.69 billion, a P/E ratio of 135.08, a P/E/G ratio of 2.79 and a beta of 0.42. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. On average, equities analysts predict that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Morgan Stanley restated an “overweight” rating and issued a $1,106.00 price target on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Truist Financial raised their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Barclays upped their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Friday, September 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a research report on Monday, September 16th. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $986.00.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.